Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.

Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof; or any combination thereof.

Abstract: In certain example embodiments, the invention provides a method of generating an ex vivo cell-based system comprising dissociating an original tissue sample obtained from a subject into a single cell population; determining an in vivo phenotype of the tissue sample by conducting single-cell RNA analysis on a first portion of the single cells; establishing an ex vivo cell-based system from a second portion of the single cells; and culturing the ex vivo cell-based system in a medium or conditions selected to maintain the in vivo phenotype. In some embodiments, the original tissue sample is a tumor tissue sample, such as a pancreatic ductal adenocarcinoma (PDAC) tumor sample.

Abstract: Inactivated antigens have only been used in avian medicine in parenterally administered vaccines. The only mucosally administered vaccines have been live, modified live, or attenuated vaccines. However, live vaccines have several disadvantages, including the risk of causing disease. Disclosed embodiments concern a composition comprising inactivated bacterial and/or viral antigens that is formulated for mucosal administration to an avian, and a method of using the composition. In certain embodiments, the composition comprises inactivated Clostridium perfringens type A antigens, and/or Salmonella spp. antigens, such as antigens from Salmonella kentucky, Salmonella typhimurium, and/or Salmonella enteriditis, or E. coli antigens. The composition may comprise a polyacrylic acid adjuvant. The composition may be administered to an avian in ovo, during the first 14 days after hatching, or after the first 14 days.

Abstract: Described in exemplary embodiments herein are methods, compositions, and kits for diagnosing, prognosing, monitoring, treating and/or preventing a hemopoietic malignancy and/or relapse thereof in a subject. In some embodiments, the methods can include determining an average cellular mass of cells in a sample from the subject and/or detecting one or more molecular signatures in one or more of the cells. In some embodiments, treatment includes administering one or more BCR-ABL tyrosine kinase inhibitors or a pharmaceutical formulation thereof, one or more pre-BCR signaling pathway inhibitors or a pharmaceutical formulation thereof, one or more p38 MAPK inhibitors or a pharmaceutical formulation thereof or any combination thereof.

Abstract: A system facilitates acquisition of virtual assets by obtaining information about a user and information about one or more computer applications associated with the user. When the user navigates a device to a catalog screen for virtual assets for computer applications, the system automatically presents to the user a filtered listing of applications for which purchasable virtual assets are available to the user that is filtered according to the information about the user and/or the information about one or more computer applications associated with the user. When the user selects an application on the filtered listing, the system automatically presents to the user a filtered catalog of purchasable virtual assets that are available to the user for the selected application that is filtered according to the information about the user and/or the information about one or more computer applications associated with the user.

Abstract: Solar cell (11; 21; 31) having a dielectric coating arranged on a back side of the solar cell (11; 21; 31) which is at least partly covered by at least one planar contact (12; 22; 32), a boundary line (14; 24; 34) of the at least one planar contact (12; 22; 32) having at least one recess (16a, 16b; 26a, 26b, 26c), and method for producing same.

Abstract: Solar cell (11; 21; 31) having a dielectric coating arranged on a back side of the solar cell (11; 21; 31) which is at least partly covered by at least one planar contact (12; 22; 32), a boundary line (14; 24; 34) of the at least one planar contact (12; 22; 32) having at least one recess (16a, 16b; 26a, 26b, 26c), and method for producing same.

Abstract: The present invention provides a method of reducing the pathogen content of sewage sludge comprising (a) adding to the sludge an effective amount of a phosphorous-containing compound and (b) keeping the phosphorous-containing compound in contact with the sludge for a sufficient time to reduce the amount of pathogens present in the sludge by an amount equivalent to a logarithmic reduction of 2 or more.

Abstract: The type III restriction enzyme EcoP15I is used to isolate from cDNA of an expressed gene a tag comprising more than 25 nucleotides and capable of identifying the expressed gene, wherein the 3? end of the tag is defined by a cleavage site of the type III restriction enzyme and the 5? end of the tag is defined by the cleavage site of another restriction enzyme that is closest to the 3? end of the cDNA of the expressed gene. The tag of the invention allows accurate quantitative gene expression analysis and rapid gene expression profiling in any organism for which no expressed sequence tag (EST) database is available.

Abstract: The present invention provides a method of reducing the pathogen content of sewage sludge comprising (a) adding to the sludge an effective amount of a phosphorous-containing compound and (b) keeping the phosphorous-containing compound in contact with the sludge for a sufficient time to reduce the amount of pathogens present in the sludge by an amount equivalent to a logarithmic reduction of 2 or more.